Vilanterol Trifenatate

The standard dosage for Vilanterol Trifenatate is highly standardized because it is delivered via fixed-dose combination inhalers.

• For COPD: The typical dose is one inhalation of the combination product (e.g., Anoro Ellipta or Breo Ellipta) once daily. In the case of Breo Ellipta, the Vilanterol component is consistently 25 mcg, paired with either 100 mcg or 200 mcg of fluticasone furoate. For Anoro Ellipta, 25 mcg of Vilanterol is paired with 62.5 mcg of umeclidinium.
• For Asthma: The recommended dose is one inhalation of the Vilanterol/Fluticasone combination (25 mcg/100 mcg or 25 mcg/200 mcg) once daily. The choice of strength depends on the patient's previous asthma therapy and disease severity.

Patients should be instructed to take their dose at the same time every day to maintain consistent bronchodilation over a 24-hour period. Taking more than one inhalation in 24 hours can significantly increase the risk of cardiovascular side effects.

Vilanterol Trifenatate is currently not approved for use in pediatric patients under the age of 18 for either asthma or COPD. The safety and efficacy of Vilanterol in children have not been established in clinical trials. Treatment for pediatric asthma usually involves different LABA/ICS combinations that have been specifically studied and approved for younger populations.

Renal Impairment

No dosage adjustment is required for patients with renal impairment. Clinical studies have shown that systemic exposure to Vilanterol is not significantly altered in patients with severe renal dysfunction.

Hepatic Impairment

No dosage adjustment is generally required for patients with mild to moderate hepatic impairment. However, Vilanterol should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C). Because Vilanterol is metabolized by the liver, systemic exposure may increase in these patients, potentially leading to more pronounced beta-adrenergic effects like increased heart rate.

Elderly Patients

No dosage adjustment is required based on age alone. However, since elderly patients are more likely to have underlying cardiovascular conditions, they should be monitored closely for changes in heart rate or blood pressure while using Vilanterol.

Proper technique with the Ellipta inhaler is critical for ensuring the medication reaches the small airways of the lungs.

1. 1Prepare: Slide the cover down until you hear a 'click.' This action peels back a foil blister inside the device and loads the dose. The dose counter will count down by one.
2. 2Exhale: Breathe out fully, away from the inhaler. Never breathe into the mouthpiece.
3. 3Inhale: Place the mouthpiece between your lips and close them firmly around it. Take a long, steady, deep breath in through your mouth. Do not block the air vent with your fingers.
4. 4Hold: Remove the inhaler from your mouth and hold your breath for about 3 to 4 seconds, or as long as comfortable.
5. 5Close: Slide the cover up and over the mouthpiece as far as it will go.
6. 6Rinse: If your combination product contains a corticosteroid (like Breo or Trelegy), rinse your mouth with water and spit it out (do not swallow) to prevent oral thrush.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at once or more than one dose in a 24-hour period. Doubling the dose can lead to excessive stimulation of the heart and nervous system.

An overdose of Vilanterol Trifenatate can lead to exaggerated beta-adrenergic effects. Symptoms may include:

• Rapid or irregular heartbeat (tachycardia/arrhythmia)
• Chest pain (angina)
• Severe tremors or shakiness
• Nervousness or anxiety
• Headache
• Muscle cramps
• Low potassium levels (hypokalemia), which can cause muscle weakness
• High blood sugar (hyperglycemia)

In the event of a suspected overdose, seek emergency medical attention immediately or contact a poison control center. Treatment typically involves supportive care and monitoring of cardiac function.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Because Vilanterol Trifenatate is administered via inhalation, many side effects are localized to the respiratory tract or are related to the drug's systemic absorption. Common side effects include:

• Nasopharyngitis: This is essentially the common cold, characterized by a sore throat, runny nose, and congestion. It is the most frequently reported side effect in clinical trials.
• Upper Respiratory Tract Infection: Patients may experience symptoms similar to a cold but involving the sinuses or throat more intensely.
• Headache: A common systemic effect that usually diminishes as the body adjusts to the medication.
• Oral Candidiasis (Thrush): While primarily caused by the corticosteroid component in combination products, Vilanterol users must be aware of white patches in the mouth or throat. Rinsing after use is essential.

• Cough and Dysphonia: Some patients may experience a persistent dry cough or hoarseness (dysphonia) due to the irritation of the powder on the vocal cords.
• Oropharyngeal Pain: General soreness in the back of the throat.
• Sinusitis: Inflammation of the sinuses leading to pressure and pain.
• Tachycardia: A noticeable increase in heart rate. Patients may feel like their heart is 'racing' even while at rest.
• Tremor: Fine shaking, particularly in the hands, caused by the stimulation of beta-receptors in the skeletal muscle.

• Atrial Fibrillation: A specific type of irregular heart rhythm that requires medical evaluation.
• Palpitations: The sensation of feeling one's own heartbeat, often described as a 'thumping' in the chest.
• Hypokalemia: A decrease in blood potassium levels, which can lead to muscle cramps or cardiac issues if severe.
• Hyperglycemia: Increased blood sugar levels, which may be a concern for patients with poorly controlled diabetes.

> Warning: Stop taking Vilanterol Trifenatate and call your doctor immediately if you experience any of these.

• Paradoxical Bronchospasm: Occasionally, an inhaled medication can cause the airways to tighten suddenly (constrict) immediately after inhalation. This is life-threatening. If you experience sudden wheezing or difficulty breathing after a dose, use your rescue inhaler and seek emergency help.
• Hypersensitivity Reactions: Signs include skin rash, hives, swelling of the face, lips, or tongue (angioedema), and difficulty swallowing or breathing. This may indicate a severe allergy to the drug or the milk proteins used as a carrier.
• Cardiovascular Complications: If you experience chest pain, significantly elevated blood pressure, or a heart rate that does not slow down, immediate medical intervention is required.
• Pneumonia (in COPD patients): Clinical trials have shown an increased risk of pneumonia in COPD patients using combinations containing Vilanterol and corticosteroids. Symptoms include fever, chills, increased mucus production, and worsening cough.

When used over years, the primary concerns involve the cardiovascular system and, if used with a corticosteroid, bone and eye health.

• Bone Mineral Density: Long-term use of combination products may slightly increase the risk of osteoporosis or fractures.
• Ocular Effects: There is a small risk of developing cataracts or glaucoma with prolonged use of inhaled respiratory maintenance therapies.
• Adrenal Suppression: Although rare with inhaled forms, long-term high-dose therapy can affect the body's natural steroid production.

Historically, the FDA required a Black Box Warning for all LABAs (including Vilanterol) regarding an increased risk of asthma-related death when used without an inhaled corticosteroid. However, based on large-scale safety trials, the FDA removed this warning in 2017 for LABAs used in combination with an ICS.

Current Status: There is currently no standalone Black Box Warning for Vilanterol when used in its approved combination forms. However, it remains a strict requirement that Vilanterol must never be used as monotherapy for asthma. In COPD, LABAs can be used without an ICS, and the risk of death is not increased in that specific population.

Report any unusual symptoms to your healthcare provider.

Vilanterol Trifenatate is a maintenance medication and is not intended for the treatment of acute bronchospasm (sudden attacks of breathlessness). Patients must always have a separate rescue inhaler (such as albuterol) available for sudden symptoms. If your breathing problems worsen quickly or your rescue inhaler does not provide relief, you must seek medical attention immediately.

As of 2026, there are no FDA black box warnings for Vilanterol Trifenatate when used in its approved combination formats (e.g., with Fluticasone or Umeclidinium). However, the FDA emphasizes that Vilanterol should not be used in asthma patients whose disease is well-controlled on low- or medium-dose inhaled corticosteroids alone.

• Allergic Reactions: Many Vilanterol products contain lactose as a carrier. While the amount of milk protein is extremely small, patients with severe milk protein allergies have experienced anaphylaxis. If you have a known severe allergy to milk, discuss this with your doctor before use.
• Cardiovascular Disease: Vilanterol, like other beta-agonists, can produce clinically significant cardiovascular effects in some patients, including increased pulse rate and blood pressure. Use with caution if you have a history of coronary insufficiency, cardiac arrhythmias, or hypertension.
• Convulsive Disorders: Use with caution in patients with seizure disorders, as beta-agonists can potentially lower the seizure threshold.
• Thyrotoxicosis: Patients with hyperthyroidism may be more sensitive to the effects of beta-agonists, which can exacerbate symptoms like tremors and rapid heart rate.
• Diabetes: Beta-agonists can increase blood glucose levels. Patients with diabetes should monitor their blood sugar more frequently when starting Vilanterol.

While Vilanterol does not require the intensive monitoring associated with some systemic drugs, your healthcare provider may perform the following:

• Lung Function Tests: Periodic spirometry (FEV1) to ensure the medication is effectively maintaining open airways.
• Potassium Levels: In patients at risk (e.g., those on certain diuretics), blood potassium may be checked periodically to screen for hypokalemia.
• Heart Rate and Blood Pressure: Regular checks during office visits to ensure no adverse cardiovascular impact.
• Eye Exams: If using a combination with a corticosteroid, regular eye exams are recommended to check for glaucoma or cataracts.

Vilanterol Trifenatate generally does not cause drowsiness or cognitive impairment. Most patients can safely drive or operate machinery. However, if you experience tremors or dizziness as a side effect, you should wait until these symptoms resolve before engaging in potentially dangerous activities.

There is no direct chemical interaction between alcohol and Vilanterol Trifenatate. However, excessive alcohol consumption can sometimes trigger asthma symptoms or worsen COPD-related inflammation. It is best to consume alcohol only in moderation while managing chronic respiratory disease.

Do not stop taking Vilanterol Trifenatate suddenly. Because it is a maintenance medication, stopping it can lead to a rapid worsening of your respiratory symptoms and an increased risk of a severe 'flare-up' or exacerbation. If you need to stop the medication, your doctor will provide a plan to transition to a different therapy.

> Important: Discuss all your medical conditions with your healthcare provider before starting Vilanterol Trifenatate.

• Other Long-Acting Beta-Agonists (LABAs): You should never use Vilanterol Trifenatate if you are already taking another LABA (such as salmeterol, formoterol, or indacaterol). Using two LABAs simultaneously significantly increases the risk of severe cardiovascular side effects and overdose.

• Strong CYP3A4 Inhibitors: Vilanterol is metabolized by the CYP3A4 enzyme. Drugs that strongly inhibit this enzyme—such as ketoconazole, ritonavir, clarithromycin, and itraconazole—can prevent the breakdown of Vilanterol. This leads to increased systemic levels of the drug, which may cause heart palpitations, high blood pressure, and low potassium. If these must be used together, your doctor will monitor you closely for 'beta-adrenergic' toxicity.
• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Medications like phenelzine or amitriptyline can prolong the QT interval (a measure of heart rhythm) and potentiate the effect of Vilanterol on the vascular system. This increases the risk of dangerous heart arrhythmias. A minimum of two weeks should pass between the use of these drugs and Vilanterol.

• Beta-Blockers: Drugs used for high blood pressure or heart conditions (e.g., propranolol, atenolol, metoprolol) can block the effects of Vilanterol. This can lead to severe bronchospasm in patients with asthma or COPD. If a beta-blocker is necessary, cardioselective beta-blockers (like metoprolol) are preferred, but they must still be used with extreme caution.
• Non-Potassium-Sparing Diuretics: Loop diuretics (like furosemide) or thiazide diuretics (like hydrochlorothiazide) can lower potassium levels. Because Vilanterol can also lower potassium, the combination may lead to severe hypokalemia.

• Caffeine: High intake of caffeine (found in coffee, tea, and energy drinks) can have a mild stimulant effect similar to Vilanterol. Combining them may increase feelings of jitteriness, nervousness, or a rapid heartbeat.
• Grapefruit: While not as significant as with oral drugs, grapefruit is a CYP3A4 inhibitor. To be safe, avoid consuming large amounts of grapefruit or grapefruit juice, as it could theoretically increase Vilanterol levels.

• St. John’s Wort: This herb is a CYP3A4 inducer, which might speed up the metabolism of Vilanterol, potentially reducing its effectiveness.
• Ephedra/Ma Huang: These contain stimulants that can dangerously increase the heart rate when combined with bronchodilators.

Vilanterol Trifenatate is not known to interfere with most common laboratory tests. However, it may cause transient increases in blood glucose and transient decreases in serum potassium, which could be reflected in metabolic panels.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Hypersensitivity to Milk Proteins: Because Vilanterol Ellipta inhalers use lactose monohydrate as a carrier, they contain trace amounts of milk proteins. Patients with a history of anaphylactic reactions to milk must not use this medication. An allergic reaction could cause airway swelling and respiratory failure.
• Hypersensitivity to Vilanterol: Any patient who has had a documented severe allergic reaction (rash, angioedema, or difficulty breathing) specifically to Vilanterol Trifenatate or any component of the formulation should not use it.
• Primary Treatment of Status Asthmaticus: Vilanterol is a long-acting maintenance drug. It must never be used in an emergency setting where rapid, intensive bronchodilation is required to save a patient's life during a severe, prolonged asthma attack (status asthmaticus).

• Unstable Cardiovascular Disease: In patients with recent myocardial infarction (heart attack), unstable angina, or severe cardiac arrhythmias, the risk of beta-agonist-induced cardiac stress may outweigh the respiratory benefits. A specialist must perform a careful risk-benefit analysis.
• Severe Hepatic Impairment: Due to the risk of increased systemic exposure, Vilanterol should be used with extreme caution in patients with Child-Pugh Class C liver disease.
• Hypokalemia or Hyperglycemia: Patients with baseline low potassium or high blood sugar may see these conditions worsen with Vilanterol use.

There is a potential for cross-sensitivity among different long-acting beta-agonists. If a patient has had a severe reaction to salmeterol or formoterol, they may also react to Vilanterol, although this is not always the case. Close medical supervision is required when switching between LABAs in sensitive individuals.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Vilanterol Trifenatate.

There are no adequate and well-controlled studies of Vilanterol Trifenatate in pregnant women. Animal studies have shown some developmental toxicity at very high doses (systemic levels much higher than those achieved by inhalation).

• Trimester-specific risks: The use of Vilanterol during labor and delivery is generally avoided because beta-agonists can interfere with uterine contractility, potentially delaying labor.
• Clinical Consideration: Poorly controlled asthma or COPD in pregnancy poses a significant risk to the fetus (e.g., low birth weight, preeclampsia). Therefore, Vilanterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is unknown whether Vilanterol is excreted in human milk. However, many drugs are excreted in breast milk, and because of the potential for adverse reactions in nursing infants from beta-agonists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Given the low systemic bioavailability of inhaled Vilanterol, the amount reaching the infant is likely very small.

Vilanterol Trifenatate is not approved for use in children or adolescents under 18 years of age. The safety and effectiveness in the pediatric population have not been established. Clinical trials in asthma for this age group have typically focused on other molecules with longer safety records in children.

Clinical trials of Vilanterol-containing products included thousands of subjects aged 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more likely to have co-existing heart disease, so they should be monitored for increased heart rate or palpitations. No dose adjustment is required for the elderly.

No dose adjustment is needed for patients with renal impairment. Studies in patients with severe renal impairment (creatinine clearance <30 mL/min) showed no significant increase in Vilanterol exposure compared to healthy subjects. Vilanterol is not significantly cleared by dialysis.

For patients with mild to moderate hepatic impairment, no dose adjustment is necessary. In patients with severe hepatic impairment, systemic exposure (AUC) to Vilanterol can increase by up to 3-fold. These patients should be monitored closely for systemic beta-agonist effects such as tremors and tachycardia.

> Important: Special populations require individualized medical assessment.

Vilanterol Trifenatate is a 'selective' long-acting beta2-adrenergic agonist. Its selectivity for beta2-receptors (found primarily in bronchial smooth muscle) is significantly higher than its affinity for beta1-receptors (found primarily in the heart). By binding to the beta2-receptor, it activates the Gs-adenylate cyclase-cAMP pathway. This leads to a decrease in intracellular calcium and relaxation of the smooth muscle fibers that wrap around the airways. This action is independent of the trigger for the bronchoconstriction (e.g., allergens, exercise, or cold air).

The bronchodilatory effect of Vilanterol is dose-dependent. In clinical studies, a dose of 25 mcg provided the optimal balance of efficacy and safety. The onset of action is relatively fast for a long-acting drug (within 5-15 minutes), but its most important feature is the 24-hour duration of effect. Unlike older LABAs, Vilanterol maintains a high level of bronchodilation throughout the entire dosing interval, preventing the 'morning dip' in lung function often experienced by COPD and asthma patients.

| Parameter | Value |

|---|---|

| Bioavailability | ~27% (inhaled) |

| Protein Binding | ~94% |

| Half-life | ~24 hours |

| Tmax | 5 to 15 minutes |

| Metabolism | Primarily CYP3A4 |

| Excretion | Renal 70%, Fecal 30% (as metabolites) |

• Molecular Formula: C24H33Cl2NO5 · C20H16O3 (as trifenatate salt)
• Molecular Weight: 774.8 g/mol (trifenatate salt)
• Solubility: Sparingly soluble in water; soluble in organic solvents like ethanol.
• Structure: It features a long lipophilic 'tail' that allows it to anchor into the cell membrane near the beta2-receptor, which explains its exceptionally long duration of action.

Vilanterol Trifenatate is classified as a Long-Acting Beta2-Adrenoceptor Agonist (LABA). It is grouped with other medications like Salmeterol, Formoterol, and Indacaterol. Within the therapeutic hierarchy, it is considered a 'Tier 2' or 'Tier 3' maintenance therapy, usually added when short-acting 'rescue' inhalers are no longer sufficient to manage symptoms.